AR092491A1 - Derivados de imidazolin-5-ona utiles como inhibidores de fasn para el tratamiento contra el cancer - Google Patents
Derivados de imidazolin-5-ona utiles como inhibidores de fasn para el tratamiento contra el cancerInfo
- Publication number
- AR092491A1 AR092491A1 ARP130103205A ARP130103205A AR092491A1 AR 092491 A1 AR092491 A1 AR 092491A1 AR P130103205 A ARP130103205 A AR P130103205A AR P130103205 A ARP130103205 A AR P130103205A AR 092491 A1 AR092491 A1 AR 092491A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- fluorinated
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se dan a conocer compuestos, composiciones y métodos para el tratamiento de varios trastornos, síndromes, enfermedades y afecciones, que incluyen aquellos mediados por la inhibición de la enzima ácido graso sintasa (FASN), tales como cáncer, obesidad y trastornos relacionados, y trastornos relacionados con el hígado. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ y R² se toman junto con el átomo de carbono al que están ligados para formar una estructura de anillos opcionalmente sustituida seleccionada del grupo que consiste en (a) cicloalquilo C₃₋₈; en donde el cicloalquilo C₃₋₈ se sustituye opcionalmente con uno a dos grupos R¹¹; (b) cicloalquilo C₅₋₆ fusionado con benzo; en donde el cicloalquilo C₅₋₆ fusionado con benzo está ligado a través de un átomo de carbono de la porción de cicloalquilo C₅₋₆ de la estructura de anillos; en donde el cicloalquilo C₅₋₆ fusionado con benzo se sustituye opcionalmente con uno a dos grupos R¹¹; y (c) heterociclilo saturado de 4 a 8 miembros; en donde el heterociclilo saturado de 4 a 8 miembros contiene un heteroátomo seleccionado del grupo que consiste en O, S y N; en donde el S se sustituye opcionalmente con uno a dos oxo; en donde el N se sustituye con R¹⁰; siempre que el heteroátomo no esté presente en la posición 2 con relación al átomo de carbono de la imidazolin-5-ona; y en donde el heterociclilo saturado de 4 a 8 miembros se sustituye opcionalmente con un grupo R¹¹ y, además se sustituye opcionalmente con un grupo R¹²; en donde R¹⁰ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, -CH₂-(alquilo C₁₋₄ sustituido con hidroxilo), alquilo C₂₋₄-O-alquilo C₁₋₄, -(alquenilo C₂₋₄), -(alquil C₁₋₄)-fenilo, -C(O)-NRARB, -C(O)-(alquil C₁₋₃)-NRARB, -C(O)-(alquilo C₁₋₄), -C(O)-(alquilo C₁₋₂ fluorizado), -C(O)-(cicloalquilo C₃₋₆), -C(O)-fenilo, -C(O)-(heteroarilo de 5 a 6 miembros), un resto de fórmula (2) ó (3), -C(O)O-(alquilo C₁₋₄), -SO₂-(alquilo C₁₋₄), SO₂-NRARB, fenilo, y heteroarilo de 5 a 6 miembros; en donde Z¹ se selecciona del grupo que consiste en -CH₂-, -O-, -N(RC)-, -S-, -S(O)- y -SO₂-; en donde RA, RB y RC se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; y en donde el fenilo o heteroarilo de 5 a 6 miembros ya sea solo o como parte de un grupo sustituyente, se sustituye, además, opcionalmente con uno a dos sustituyentes independientemente seleccionados del grupo que consiste en halógeno, hidroxilo, ciano, NRARB, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alcoxi C₁₋₄, y alcoxi C₁₋₄ fluorizado; en donde cada R¹¹ se selecciona independientemente del grupo que consiste en hidroxi, oxo, halógeno, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alcoxi C₁₋₄, alcoxi C₁₋₄ fluorizado, alquilo C₁₋₄ sustituido con hidroxi, -(alquilo C₁₋₄)-O-(alquilo C₁₋₄), -(alquilo C₁₋₄)-fenilo, -ciano, -NRDRE, -C(O)-NRDRE, -C(O)-(alquilo C₁₋₄), -C(O)-fenilo, -C(O)-(heteroarilo de 5 a 6 miembros), un resto de fórmula (2) ó (4), -C(O)OH, -C(O)O-(alquilo C₁₋₄), -SO₂-(alquilo C₁₋₄), SO₂-NRDRE, fenilo y heteroarilo de 5 a 6 miembros; en donde Z² se selecciona del grupo que consiste en -CH₂-, -O-, -N(RC)-, -S-, -S(O)- y -SO₂-; en donde RD, RE y RF se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; y en donde el fenilo o heteroarilo de 5 a 6 miembros ya sea solo o como parte de un grupo sustituyente, se sustituye, además, opcionalmente con uno a dos sustituyentes independientemente seleccionados del grupo que consiste en halógeno, hidroxi, ciano, NRDRE, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alcoxi C₁₋₄ y alcoxi C₁₋₄ fluorizado; y en donde R¹² se selecciona del grupo que consiste en hidroxi, oxo, halógeno, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alcoxi C₁₋₄, alcoxi C₁₋₄ fluorizado, y alquilo C₁₋₄ sustituido con hidroxi; m es un entero de 0 a 1; y n es un entero de 0 a 2; siempre que, cuando n es 2, entonces m es 1; el resto de fórmula (5) selecciona del grupo que consiste en azetidin-3-ilo, pirrolidin-3-ilo, pirrolidin-3R-ilo, pirrolidin-3S-ilo, piperidin-3-ilo, piperidin-3R-ilo, piperidin-2S-ilo, y piperidin-4-ilo; a es un entero de 0 a 1; L¹ se selecciona del grupo que consiste en -C(O)-, -C(O)O-, -C(O)-NRL-, -C(S)-, -SO₂-, y -SO₂-NRL; en donde RL se selecciona de grupo que consiste en hidrógeno y alquilo C₁₋₄; R³ se selecciona del grupo que consiste en alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alquilo C₁₋₄ sustituido con hidroxi, alquenilo C₂₋₄, cicloalquilo C₃₋₆, -(alquilo C₁₋₄)-(cicloalquilo C₃₋₆), heterociclilo saturado de 4 a 6 miembros, -(alquilo C₁₋₄)-(heterociclilo saturado de 4 a 6 miembros), -(alquenilo C₂₋₄)-(heterociclilo saturado de 5 a 6 miembros), heteroarilo de 5 a 6 miembros, -(alquilo C₁₋₄)-(heteroarilo de 5 a 6 miembros), -(alquenilo C₂₋₄)-(heteroarilo de 5 a 6 miembros), y NRVRW; en donde RV y RW se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; en donde cicloalquilo C₃₋₆, heterociclilo saturado de 4 a 6 miembros o heteroarilo de 5 a 6 miembros, ya sea solo o como parte de un grupo sustituyente, se sustituyen opcionalmente con uno a dos sustituyentes independientemente seleccionados del grupo que consiste en halógeno, hidroxilo, ciano, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, -(alquilo C₁₋₄)-OH, alcoxi C₁₋₄, alcoxi C₁₋₄ fluorizado, y NRGRH; en donde RG y RH se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; el resto de fórmula (6) se selecciona del grupo que consiste en el grupo de formulas (7); b es un entero de 0 a 2; cada R⁴ se selecciona independientemente del grupo que consiste en hidroxi, halógeno, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alcoxi C₁₋₄, alcoxi C₁₋₄ fluorizado, ciano, y NRJRK; en donde RJ y RK se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; siempre que cada grupo R⁴ esté ligado a un átomo de carbono; siempre que, cuando el resto de fórmula (6) se selecciona del grupo que consiste en el grupo de formulas (8), y esté sustituido con -(R⁴)ᵇ, entonces b es un entero de 0 a 1; R⁵ se selecciona del grupo que consiste en (a) el compuesto de formula (9)y (b) el compuesto de fórmula (10); en donde el anillo A¹ se selecciona del grupo que consiste en arilo, heteroarilo y heterociclilo parcialmente insaturado; c es un entero de 0 a 2; cada R⁶ se selecciona independientemente del grupo que consiste en hidroxi, oxo, halógeno, ciano, nitro, alquilo C₁₋₄, alquilo C₁₋₄ fluorizado, alquilo C₁₋₄ sustituido con hidroxi, -(alquilo C₁₋₄)-CN, -(alquilo C₁₋₄)-O-(alquilo C₁₋₄, alcoxi C₁₋₄, alcoxi C₁₋₄ fluorizado, -SO₂-(alquilo C₁₋₄), -NRMRN, -(alquilo C₁₋₄)-NRPRQ, -C(O)-(alquilo C₁₋₄), -C(O)-(alquilo C₁₋₂ fluorizado), -C(O)-NRMRN, -C(O)OH, -C(O)O-(alquilo C₁₋₄), -NRM-C(O)H, -NRM-C(O)-(alquilo C₁₋₄), -NRM-SO₂-(alquilo C₁₋₄), cicloalquilo C₃₋₆, -ciano-(cicloalquilo C₃₋₆), -(alquilo C₁₋₄)-(cicloalquilo C₃₋₆), -S-(cicloalquilo C₃₋₆), -SO-(cicloalquilo C₃₋₆), -SO₂-(cicloalquilo C₃₋₆), -NH-(cicloalquilo C₃₋₆), -NH-SO₂-(cicloalquilo C₃₋₆), oxetanilo, -(alquilo C₁₋₂)-oxetanilo, tetrahidrofuranilo, -(alquilo C₁₋₂)-tetrahidro-furanilo, tetrahidropiranilo, y -(alquilo C₁₋₂)-tetrahidro-piranilo; en donde RM y RN se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; en donde RP y RQ se seleccionan independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄; alternativamente RP y RQ se toman junto con el átomo de nitrógeno al que están ligados para formar un heterociclilo saturado de 5 a 6 miembros; tal heterociclilo saturado de 5 a 6 miembros se sustituye opcionalmente con un sustituyente seleccionado del grupo que consiste en halógeno, alquilo C₁₋₄, y alquilo C₁₋₄ fluorizado; en donde el anillo A² se selecciona
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261698125P | 2012-09-07 | 2012-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092491A1 true AR092491A1 (es) | 2015-04-22 |
Family
ID=49170933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103205A AR092491A1 (es) | 2012-09-07 | 2013-09-09 | Derivados de imidazolin-5-ona utiles como inhibidores de fasn para el tratamiento contra el cancer |
Country Status (6)
Country | Link |
---|---|
US (3) | US20150099730A1 (es) |
EP (1) | EP2892892B1 (es) |
JP (1) | JP6285442B2 (es) |
AR (1) | AR092491A1 (es) |
CA (1) | CA2884355C (es) |
WO (1) | WO2014039769A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
EP2892892B1 (en) * | 2012-09-07 | 2017-05-31 | Janssen Pharmaceutica NV | Imidazolin-5-one derivatives useful as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
CA2934257C (en) * | 2013-12-17 | 2022-06-07 | Janssen Pharmaceutica Nv | Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer |
EP3220901B1 (en) | 2014-11-20 | 2020-02-19 | VIB vzw | Means and methods for treatment of early-onset parkinson's disease |
MX2017016669A (es) | 2015-06-18 | 2018-04-13 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos. |
EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
WO2018089904A1 (en) * | 2016-11-11 | 2018-05-17 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US10902613B2 (en) | 2019-03-20 | 2021-01-26 | Bi Incorporated | Systems and methods for textural zone identification |
US10692345B1 (en) | 2019-03-20 | 2020-06-23 | Bi Incorporated | Systems and methods for textural zone monitoring |
US10893383B2 (en) | 2019-05-06 | 2021-01-12 | Bi Incorporated | Systems and methods for monitoring system equipment diagnosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633650A (zh) * | 2002-07-01 | 2010-01-27 | 法斯根有限责任公司 | 新化合物、包含该化合物的药物组合物及该化合物的应用方法 |
US7649012B2 (en) * | 2002-07-09 | 2010-01-19 | Fasgen, Inc. | Compounds, pharmaceutical compositions containing same, and methods of use for same |
AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
BRPI0510397A (pt) * | 2004-05-26 | 2007-11-13 | Fasgen Llc | compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos |
US20130172384A1 (en) * | 2010-09-17 | 2013-07-04 | Glaxosmithkline Intellectual Property Development Limited | Fatty acid synthase inhibitors |
EP2892892B1 (en) * | 2012-09-07 | 2017-05-31 | Janssen Pharmaceutica NV | Imidazolin-5-one derivatives useful as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
-
2013
- 2013-09-06 EP EP13762696.6A patent/EP2892892B1/en active Active
- 2013-09-06 US US14/020,122 patent/US20150099730A1/en not_active Abandoned
- 2013-09-06 WO PCT/US2013/058416 patent/WO2014039769A1/en active Application Filing
- 2013-09-06 CA CA2884355A patent/CA2884355C/en not_active Expired - Fee Related
- 2013-09-06 JP JP2015531220A patent/JP6285442B2/ja not_active Expired - Fee Related
- 2013-09-09 AR ARP130103205A patent/AR092491A1/es unknown
-
2015
- 2015-09-11 US US14/851,738 patent/US10077261B2/en active Active
-
2018
- 2018-07-19 US US16/040,004 patent/US20180327401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10077261B2 (en) | 2018-09-18 |
JP2015527397A (ja) | 2015-09-17 |
CA2884355C (en) | 2022-05-17 |
EP2892892A1 (en) | 2015-07-15 |
JP6285442B2 (ja) | 2018-02-28 |
US20180327401A1 (en) | 2018-11-15 |
US20150099730A1 (en) | 2015-04-09 |
WO2014039769A1 (en) | 2014-03-13 |
US20160002219A1 (en) | 2016-01-07 |
CA2884355A1 (en) | 2014-03-13 |
EP2892892B1 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092491A1 (es) | Derivados de imidazolin-5-ona utiles como inhibidores de fasn para el tratamiento contra el cancer | |
AR090618A1 (es) | Proceso para la preparacion de inhibidores de sglt2 de derivados de bencilbenceno | |
AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
AR089939A1 (es) | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 | |
AR102948A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 | |
AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR090161A1 (es) | Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga | |
AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
AR104720A1 (es) | Moduladores de ccr2 | |
AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
AR088449A1 (es) | Benzilindazoles sustituidos | |
RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
AR092253A1 (es) | Inhibidores de serina/treonina cinasa | |
AR098002A1 (es) | Preparación de derivados hidroxi-bencilbenceno | |
AR075367A1 (es) | Inhibidores de glucosilceramida sintasa | |
AR087792A1 (es) | Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
ES2613753T3 (es) | Proceso para la preparación de derivados de esterol | |
AR082004A1 (es) | Compuestos de fusion de piridina | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
AR098647A1 (es) | Inhibidores de serina / treonina cinasa | |
AR087563A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |